[Immunity indices in patients with cancer of the uterine body treated with 17-alpha-oxyprogesterone-capronate].
Based on the findings in 163 endometrial cancer patients, it is shown that following their treatment with 17-alpha-oxyprogesterone-capronate (17-OPC) there occur differential changes in some indices of the cell and humoral immunity: less frequent positive results of delayed hypersensitivity reaction (DHR) with the tumor-associated antigen and more frequent ones with tuberculin; less number of positive responses of the Hougne microprecipitation reaction with tumor-associated and embryonal antigens. Simultaneously, the same patients show a reduced functional activity of immune lymphocytes -- RBT and RSFSR.
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007111:Immunity, Cellular; D008214:Lymphocytes / Q000276:immunology*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000276:immunology
D006908:Hydroxyprogesterones
Pokazateli immuniteta u bol'nykh rakom tela matki, lechennykh 17-al'fa-oksiprogesteron-kapronatom.